Search
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.[L51129]
Clesrovimab
go.drugbank.com/drugs/DB18877Approved[A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]
Prothrombin
go.drugbank.com/drugs/DB11311ApprovedInvestigationalProthrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.
Mixtures: OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETInfluenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB10998ApprovedInvestigationalWithdrawnA seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposin...
Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 Kit, Medical Provider Single Use EZ Flu Shot Flucelvax 2015-2016Collagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigational[L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women.
Cefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie.
International brands: Xi Fu NiInotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[L938] A month later, inotuzumab ozogamicin was also approved by the FDA.[L50542]
Istradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigational[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213]
Taurolidine
go.drugbank.com/drugs/DB12473ApprovedInvestigational[A263217] In November 2023, a catheter lock solution of taurolidine in combination with [heparin] - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial